Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 1-4 , March 2007

The true impact of new targeted therapies for AML

  • Jacob M. Rowe, MD (Director)

      Affiliations

    • Corresponding Author InformationTel.: +972 4 854 2541; Fax: +972 4 854 2343.

References 

  1. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–572
  2. Rowe JM. Targeted therapy in leukemia – why and for whom?. In:  Dicke KA,  Keating A editor. Stem cell and targeted therapy. Charlottesville, Virginia: Carden & Jennings Publishing; 2003;p. 3–11
  3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine. 2001;344:1031–1036
  4. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. The New England Journal of Medicine. 2004;350:1605–1616

PII: S1521-6926(06)00082-X

doi: 10.1016/j.beha.2006.11.003

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 1-4 , March 2007

Article Tools

* Image Usage & Resolution